MedPath

CAMCEVI

These highlights do not include all the information needed to use CAMCEVI safely and effectively. See full prescribing information for CAMCEVI.

Approved
Approval ID

d7a8761a-d953-413a-e053-2a95a90a60ee

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Apr 3, 2023

Manufacturers
FDA

Accord BioPharma, Inc.

DUNS: 079636487

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

LEUPROLIDE

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code69448-014
Application NumberNDA211488
Product Classification
M
Marketing Category
C73594
G
Generic Name
LEUPROLIDE
Product Specifications
Route of AdministrationSUBCUTANEOUS
Effective DateApril 3, 2023
FDA Product Classification

INGREDIENTS (3)

METHYLPYRROLIDONEInactive
Quantity: 136 mg in 0.37 g
Code: JR9CE63FPM
Classification: IACT
POLYLACTIDEInactive
Quantity: 184 mg in 0.37 g
Code: 459TN2L5F5
Classification: IACT
LEUPROLIDE MESYLATEActive
Quantity: 42 mg in 0.37 g
Code: 8E3C3C493W
Classification: ACTIM

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

CAMCEVI - FDA Drug Approval Details